Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure.

Gard DE, Kring AM, Gard MG, Horan WP, Green MF.

Schizophr Res. 2007 Jul;93(1-3):253-60. Epub 2007 May 9.

2.

Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia.

Gur RE, Nimgaonkar VL, Almasy L, Calkins ME, Ragland JD, Pogue-Geile MF, Kanes S, Blangero J, Gur RC.

Am J Psychiatry. 2007 May;164(5):813-9.

PMID:
17475741
3.

Effortful cognitive resource allocation and negative symptom severity in chronic schizophrenia.

Granholm E, Verney SP, Perivoliotis D, Miura T.

Schizophr Bull. 2007 May;33(3):831-42. Epub 2006 Sep 6.

4.

Recent advances in social skills training for schizophrenia.

Kopelowicz A, Liberman RP, Zarate R.

Schizophr Bull. 2006 Oct;32 Suppl 1:S12-23. Epub 2006 Aug 2. Review.

5.

The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements.

Harvey PD, Green MF, Bowie C, Loebel A.

Psychopharmacology (Berl). 2006 Aug;187(3):356-63. Epub 2006 Jun 17.

PMID:
16783539
6.

The NIMH-MATRICS consensus statement on negative symptoms.

Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR.

Schizophr Bull. 2006 Apr;32(2):214-9. Epub 2006 Feb 15. No abstract available.

7.

Anhedonia in schizophrenia: a review of assessment strategies.

Horan WP, Kring AM, Blanchard JJ.

Schizophr Bull. 2006 Apr;32(2):259-73. Epub 2005 Oct 12. Review.

8.

Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia.

Bromet EJ, Naz B, Fochtmann LJ, Carlson GA, Tanenberg-Karant M.

Schizophr Bull. 2005 Jul;31(3):639-49. Epub 2005 Jun 23.

PMID:
15976012
9.

The negative symptoms of schizophrenia: a cognitive perspective.

Rector NA, Beck AT, Stolar N.

Can J Psychiatry. 2005 Apr;50(5):247-57. Review.

PMID:
15968839
10.

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR.

Schizophr Bull. 2005 Jan;31(1):5-19. Epub 2005 Feb 16.

PMID:
15888422
11.

The Indianapolis Vocational Intervention Program: a cognitive behavioral approach to addressing rehabilitation issues in schizophrenia.

Davis LW, Lysaker PH, Lancaster RS, Bryson GJ, Bell MD.

J Rehabil Res Dev. 2005 Jan-Feb;42(1):35-45.

12.
13.

The Penn Conditional Exclusion Test: a new measure of executive-function with alternate forms of repeat administration.

Kurtz MM, Ragland JD, Moberg PJ, Gur RC.

Arch Clin Neuropsychol. 2004 Mar;19(2):191-201.

14.

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM.

Am J Psychiatry. 2004 Mar;161(3):473-9.

PMID:
14992973
15.

THINKING AND DEPRESSION. I. IDIOSYNCRATIC CONTENT AND COGNITIVE DISTORTIONS.

BECK AT.

Arch Gen Psychiatry. 1963 Oct;9:324-33. No abstract available.

PMID:
14045261
16.

Development of an abbreviated schizophrenia quality of life scale using a new method.

Bilker WB, Brensinger C, Kurtz MM, Kohler C, Gur RC, Siegel SJ, Gur RE.

Neuropsychopharmacology. 2003 Apr;28(4):773-7. Epub 2002 Oct 17.

17.

Mediation in experimental and nonexperimental studies: new procedures and recommendations.

Shrout PE, Bolger N.

Psychol Methods. 2002 Dec;7(4):422-45.

PMID:
12530702
19.

Motivational beliefs, values, and goals.

Eccles JS, Wigfield A.

Annu Rev Psychol. 2002;53:109-32. Review.

PMID:
11752481
20.

Computerized neurocognitive scanning: II. The profile of schizophrenia.

Gur RC, Ragland JD, Moberg PJ, Bilker WB, Kohler C, Siegel SJ, Gur RE.

Neuropsychopharmacology. 2001 Nov;25(5):777-88.

Supplemental Content

Support Center